Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Genes|January 24, 2019
Writing Histone Monoubiquitination in Human Malignancy-The Role of RING Finger E3 Ubiquitin LigasesDeborah J Marsh, Kristie-Ann DicksonCancers|November 25, 2020
Histone Monoubiquitination in Chromatin Remodelling: Focus on the Histone H2B Interactome and CancerDeborah J Marsh, Yue Ma, Kristie-Ann DicksonInternational Journal of Molecular Sciences|August 27, 2021
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian CancerKristie-Ann Dickson, Tao Xie, Christian Evenhuis, et al.Cancer Letters|October 6, 2024
SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodelingNatisha R Field, Kristie-Ann Dickson, Najah T Nassif, et al.Frontiers in Bioengineering and Biotechnology|February 28, 2022
Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized MedicineChristine Yee, Kristie-Ann Dickson, Mohammed N Muntasir, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 7, 2025
Drug repurposing in gynaecological cancers: Proven drugs for new challengesAmani Alghalayini, Farhana A Sarker, Kristie-Ann Dickson, et al.Journal of Materials Chemistry. B|October 22, 2021
An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticlesNidhi Joshi, Dongli Liu, Kristie-Ann Dickson, et al.Human Molecular Genetics|October 25, 2011
The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitinationMichael A Hahn, Kristie-Ann Dickson, Stuart Jackson, et al.Pharmaceutics|April 23, 2022
The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer CellsDongli Liu, Gunnar F Kaufmann, James B Breitmeyer, et al.Cancers|October 14, 2022
Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall SurvivalTao Xie, Kristie-Ann Dickson, Christine Yee, et al.Pageof 3